INTS vs JLL
Intensity Therapeutics, Inc. Common stock (INTS) versus Jones Lang LaSalle Incorporated (JLL) — a side-by-side from cached financials, not a winner call.
Intensity Therapeutics, Inc. Common stock (INTS) is a biotechnology company listed on US.
Jones Lang LaSalle Incorporated (JLL) is a real estate services company listed on US.
INTS does not have a complete income-statement cache yet.
Latest reported JLL revenue for 2024-12-31 was $23.43B. Net income was $546.8M. Revenue was up 12.9% from 2023-12-31 to 2024-12-31. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
INTS currently screens at market cap $7.7M. JLL currently screens at market cap $12.12B and trailing P/E 23.0.
Not investment advice. Open the INTS and JLL stock pages for the full models.
Not investment advice.